Zollinger-Ellison syndrome is a rare condition, in which one or more tumors form in duodenum and pancreas. These tumors, called gastrinoma, secrete large amount of gastrin hormone, which causes stomach to produce too much acid. Excess secretion of acid leads to peptic ulcer as well as diarrhea. Zollinger-Ellison syndrome can occur at age; however, people are usually diagnosed between 20 and 50. Signs and symptoms of the syndrome include abdominal pain, diarrhea, acid reflux and heart burn, and bleeding in digestive tract. Exact nature and cause of Zollinger-Ellison syndrome is unknown. However, it can be caused by autosomal dominant inherited syndrome called multiple endocrine neoplasia type 1 (MEN-1). About 25% people who have Zollinger-Ellison syndrome have them as part of MEN-1. Diagnosis of Zollinger-Ellison syndrome is done through study of medical history, blood test, upper gastrointestinal endoscopy, endoscopic ultrasound, imaging tests such as magnetic resonance imaging (MRI), CT scan, and ultrasound. The objective of the treatment of Zollinger-Ellison syndrome is elimination of excess acid production, ulcer disease, and malignant tumor. Tumor removal is achieved through surgery and excess acid secretion is stopped using drugs such as proton pump inhibitors, H2-receptor antagonist, antacids, and chemotherapy. The class of drugs known as proton pump inhibitor, which include omeprazole, decreases acid production and promotes ulcer healing in patients with Zollinger-Ellison syndrome. In 2017, clinical trials were conducted on patients with Zollinger-Ellison syndrome. The aim was to study various aspects of treatment of Zollinger-Ellison syndrome which include usage of Interferon, octreotide, or their combination.
Improved understanding of the pathogenesis of gastrinoma, new diagnostic system, and new treatment strategy are projected to drive the global Zollinger-Ellison syndrome treatment market during the forecast period. Additionally, rise in prevalence of other endocrine tumors and emergence of new treatment technologies are anticipated to propel the global Zollinger-Ellison syndrome treatment market in the near future. However, poor pipeline productivity and side effects of drugs are expected to restrain the global market from 2018 to 2026. Changes in pricing policies of drugs is another factor likely to hamper the growth of the market in the next few years.
The global Zollinger-Ellison syndrome treatment market can be segmented based on drug type, route of administration, distribution channel, and region. In terms of drug type, the global market can be categorized into antacids, H2 antagonists, proton pump inhibitors, phosphate binders, and others. Based on route of administration, the global Zollinger-Ellison syndrome treatment market can be bifurcated into oral and injectable. In terms of distribution channel, the global market can be divided into online pharmacies, retail pharmacies, and hospital pharmacies.
Geographically, the global Zollinger-Ellison syndrome treatment market can be segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America is expected to account for the largest share of the global market from 2018 to 2026, due to rise in incidence of the syndrome. Europe is expected to be the second largest market for Zollinger-Ellison syndrome treatment during the forecast period, due to high number of patents that are likely to expire, thereby enabling the entry of generics. The Zollinger-Ellison syndrome treatment market in Asia Pacific is expected to expand rapidly during the forecast period. Growth of the market in the region can be attributed to increase in demand for anti-cancer drugs and rapidly developing health care infrastructure.
Key players operating in the global Zollinger-Ellison syndrome treatment market are Sanofi, Novartis International AG, Johnson & Johnson, Lupin Limited, Alembic Pharmaceuticals Ltd., Baxter International, Inc., Mylan N.V., Wockhardt Ltd., Apotex, Inc., Aurobindo Pharma Ltd., GlaxoSmithKline plc, Teva Pharmaceuticals USA, and Bio-Pharm, Inc.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.